Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative SOX + nab-paclitaxel + sintilimab for HER2-negative hepatoid adenocarcinoma of the stomach (Phase II)
ChiCTR2500106402Phase 2Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jul 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab, paclitaxel, oxaliplatin and tegafur + gimeracil + oteracil in Gastric hepatoid carcinoma (GHC), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: pathological complete response rate. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
sintilimabpaclitaxeloxaliplatintegafur + gimeracil + oteracil
03
Conditions
Gastric hepatoid carcinoma (GHC)
Beyond the preview
Go deeper on ChiCTR2500106402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106402.